IMDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesUS GAAP · USD

Insight Molecular Diagnostics Inc.

Insight Molecular Diagnostics Inc. (iMDx) develops molecular diagnostic test kits and related laboratory services aimed at decentralizing testing away from central labs. The company’s model is built around transplant and other biomarker-based testing that hospitals, transplant centers, labs, and research institutions can run themselves to support clinical decisions and research studies.

Kysy yhtiöstä
Liikevaihto4,1milj. USD
+115,6 %v/v
Liikevoitto (EBIT)−51,1milj. USD
+16,2 %v/v
EBIT-marginaali−1 260,8%
+1 984,4 %-yks.v/v
Nettotulos−50,2milj. USD
+17,2 %v/v
Vapaa kassavirta−25,4milj. USD
−19,6 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−80−60−40−20020milj. USD2020: 1,2 milj. USD2020: EBIT −30 milj. USD20202021: 2,2 milj. USD2021: EBIT −74 milj. USD20212022: 0,96 milj. USD2022: EBIT −18 milj. USD20222023: 1,5 milj. USD2023: EBIT −25 milj. USD20232024: 1,9 milj. USD2024: EBIT −61 milj. USD20242025: 4,1 milj. USD2025: EBIT −51 milj. USD20254,1−51
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Kitted molecular diagnostic tests55 %

Decentralized test kits sold to customer labs and research users to run testing in-house.

Laboratory Developed Tests (LDTs)20 %

Clinical testing performed by iMDx on patient samples, historically including DetermaRx-related services.

Laboratory Services15 %

Assay development and clinical testing services performed for life sciences and biotechnology customers.

Research-use-only products10 %

RUO transplant and biomarker assays sold for research applications rather than clinical diagnosis.

Tuotteet

Raportoitu · osuus liikevaihdosta
99,4%FY2025100 %
  • Laboratory Services99,4 %
  • Kitted Products0,6 %

Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

iMDx sells primarily to hospitals, transplant centers, laboratories, and research institutions that want to run molecular tests internally rather than send samples to a central lab. Its users include clinicians and scientific decision-makers such as surgeons, nephrologists, oncologists, pathologists, lab directors, and chief medical officers, who value faster access to biomarker data and more control over testing workflows.

Hospitals and health systems

Buy diagnostic kits and clinical tests to support patient-care decisions and reduce reliance on central labs.

Transplant centers

Use transplant monitoring assays such as GraftAssureIQ to track donor-derived biomarkers and guide care.

Clinical laboratories

Adopt iMDx tests to expand in-house molecular testing capabilities and improve turnaround time.

Research institutions and laboratory customers

Purchase RUO kits and services to run biomarker studies and generate data for scientific research.

Life sciences and biotechnology companies

Buy assay development and clinical testing services for product development and evidence generation.

Strategia

iMDx is shifting toward commercialization of transplant kitted tests while continuing to support laboratory services and other assay development work. Management also wants to broaden market access through distributors, licensing, or joint ventures, while managing cash carefully until reimbursement and scale improve.

Commercialize transplant kitted testsLyhyt aikaväli

The company says future laboratory services revenue will be affected by its shift toward transplant kitted products.

Expand U.S. direct sales and customer adoptionLyhyt aikaväli

A direct sales force can accelerate adoption in hospitals, transplant centers, and labs.

Enter overseas markets through lower-capital modelsKeskipitkä aikaväli

Distributors, licensing, or joint ventures can reduce capital needs and speed international entry.

Secure reimbursement and regulatory pathwaysKeskipitkä aikaväli

Medicare coverage and FDA/foreign approvals are essential for broad clinical commercialization.

Maantiede

Q1/2026

iMDx is headquartered in the United States and intends to commercialize its diagnostic tests domestically through its own sales force. The company also said it is pursuing distributors and other commercialization arrangements in foreign markets, which makes overseas expansion an important part of its growth plan and a source of regulatory and execution risk.

USA100 %

Riskit

iMDx is exposed to regulatory, reimbursement, and financing risk because its clinical diagnostics depend on FDA/CMS pathways and payer acceptance. The company also faces execution risk from shifting its business mix toward kitted products, while laboratory services can be volatile because revenue is tied to discrete projects and customer timing.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →FDA and foreign regulatory approval risk1Medicare reimbursement and MAC coverage risk2Regulatory reclassification of LDTs3Revenue concentration and project timing risk5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. FDA and foreign regulatory approval riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    IVD products may require clearance or approval before sale, and current LDT positioning could be challenged.

    Kohdistuu: Clinical diagnostic products

  2. Medicare reimbursement and MAC coverage riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Coverage decisions under MolDx and MAC policies are critical to commercialization and claims payment.

    Kohdistuu: Clinical molecular diagnostics

  3. Regulatory reclassification of LDTsVaikutus: KorkeaTodennäköisyys: Kohtalainen

    If tests are deemed IVDs rather than LDTs, they may need to be withdrawn until authorized.

    Kohdistuu: Existing marketed tests

  4. Financing and dilution riskVaikutus: Korkea

    Management says additional capital will be needed to fund operations and product launch.

    Kohdistuu: Operating runway

  5. Revenue concentration and project timing riskVaikutus: KeskitasoTodennäköisyys: Matala

    Laboratory Services are discrete, time-and-materials projects that can vary materially by period.

    Kohdistuu: Laboratory Services

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition for Laboratory Services

Revenue is recognized when services are completed, but discrete projects can shift timing between periods.

Vaikutus: Can create volatility in quarterly revenue and margins

Payment-based recognition for some LDT revenue

For certain payers, revenue is recognized upon payment because collection and reimbursement are uncertain.

Vaikutus: Affects timing of reported revenue and receivables

Contingent consideration liabilities

Royalty or revenue-share obligations are valued using scenario analysis and management assumptions.

Vaikutus: Can create fair value gains/losses and earnings volatility

Intangible asset and long-lived asset impairment

Acquired IP and other assets depend on future commercialization success.

Vaikutus: Could lead to non-cash write-downs if expected cash flows weaken

Going concern assessment

The company states it will need additional capital to fund operations.

Vaikutus: Important for liquidity analysis and financial statement interpretation

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

MDxHealth SA

MDXH · Services-Medical Laboratories

IDEXX Laboratories, Inc

IDXX · In Vitro & In Vivo Diagnostic Substances

Co-Diagnostics, Inc.

CODX · Surgical & Medical Instruments & Apparatus

CareDx, Inc.

CDNA · Services-Medical Laboratories

MiMedx Group, Inc

MDXG · Surgical & Medical Instruments & Apparatus

GeneDx Holdings Corp.

WGS · Services-Health Services

Päivitetty: 24.9.2026

Insight Molecular Diagnostics Inc. (IMDX) liikevaihto, tulos ja tunnusluvut 2025 – Clarifo